New stent surface materials: The impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets

Acta Biomaterialia

Volumn 10, Issue 2, 2014, Pages 688-700

  Busch, Raila ^a   Strohbach, Anne ^a   Rethfeldt, Stefanie ^a   Walz, Simon ^a   Busch, Mathias ^a   Petersen, Svea ^b   Felix, Stephan ^a   Sternberg, Katrin ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Biodegradable polymers; Endothelial cells; Platelets; Smooth muscle cells; Stents

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADABLE POLYMERS; CELL PROLIFERATION; DISEASES; ETHYLENE; MUSCLE; PLASTIC COATINGS; PLATELETS; POLYMERIC IMPLANTS; STENTS;

4-HYDROXYBUTYRATE; BLOOD AND TISSUES; BLOOD CELLS; ENDOTHELIAL-CELLS; POLY (ETHYLENE-CO-VINYL ACETATE); POLY (L-LACTIDE); POLYMERIC BLENDS; SMOOTH MUSCLE CELLS; STENT COATINGS; TISSUE CELLS;

ENDOTHELIAL CELLS;

CD31 ANTIGEN; POLY(3 HYDROXYBUTYRIC ACID); POLY(4 HYDROXYBUTYRATE); POLY(ETHYLENE CO VINYLACETATE); POLYBUTYLMETHACRYLATE; POLYESTER; POLYLACTIDE; POLYMER; UNCLASSIFIED DRUG;

ARTERY MUSCLE; ARTICLE; BIOCOMPATIBILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ELUTING STENT; ENDOTHELIUM CELL; GLYCOCALYX; HUMAN; HUMAN CELL; POLYMERIZATION; PRIORITY JOURNAL; SHEAR STRESS; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOGENICITY; VASCULAR IMPLANT; VASCULAR STENT;

BIODEGRADABLE POLYMERS; ENDOTHELIAL CELLS; PLATELETS; SMOOTH MUSCLE CELLS; STENTS;

ANTIGENS, CD31; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELL COMMUNICATION; CELL PROLIFERATION; CELL SURVIVAL; COATED MATERIALS, BIOCOMPATIBLE; GLYCOCALYX; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE SYNTHASE TYPE III; P-SELECTIN; PLATELET ADHESIVENESS; PLATELET AGGREGATION; POLYMERS; RHEOLOGY; STENTS; STRESS, MECHANICAL; SURFACE PROPERTIES;

EID: 84894633864     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2013.10.015     Document Type: Article

References (63)

1. M.C. Morice et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial J Am Coll Cardiol 50 2007 1299 1304
2. S. Garg, and P.W. Serruys Coronary stents: current status J Am Coll Cardiol 56 2010 S1 S42
3. E. Regar et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size Circulation 106 2002 1949 1956
4. U. Stenestrand et al. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) Eur Heart J 31 2010 177 186
5. S. Elezi, A. Kastrati, F.J. Neumann, M. Hadamitzky, J. Dirschinger, and A. Schomig Vessel size and long-term outcome after coronary stent placement Circulation 98 1998 1875 1880
6. K.L. Kennedy, A.R. Lucas, and W. Wan Local delivery of therapeutics for percutaneous coronary intervention Curr Drug Deliv 8 2011 534 556
7. A. Seidlitz et al. Examination of drug release and distribution from drug-eluting stents with a vessel-simulating flow-through cell Eur J Pharm Biopharm 78 2011 36 48
8. E. Regar et al. A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients Catheter Cardiovasc Interv 78 2011 710 717
9. R.A. Anderson, F. Fath-Ordoubadi, S. Younas, A. Bainbridge, R.A. Swallow, K.D. Dawkins, and N.P. Curzen Drug-eluting stents for the treatment of in-stent restenosis-'real world' double centre experience in consecutive patients Int J Cardiovasc Intervent. 7 4 2005 188 192
10. D.J. Kereiakes et al. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials EuroIntervention 7 2011 74 83
11. C. Simsek et al. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries JACC Cardiovasc Interv 3 2010 1051 1058
12. J. Daemen et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
13. P. Lanzer, K. Sternberg, K.P. Schmitz, F. Kolodgie, G. Nakazawa, and R. Virmani Drug-eluting coronary stent very late thrombosis revisited Herz 33 2008 334 342
14. J.R. Nebeker et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project J Am Coll Cardiol 47 2006 175 181
15. K.N. Huang, S.M. Grandi, K.B. Filion, and M.J. Eisenberg Late and very late stent thrombosis in patients with second-generation drug-eluting stents Can J Cardiol 2013 10.1016/j.cjca.2013.04.001
16. H. Kitabata, J.P. Loh, L.K. Pendyala, S. Badr, D. Dvir, and I.M. Barbash et al. Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents Am J Cardiol 111 8 2013 1092 1098
17. H. Dores, L. Raposo, R. Campante Teles, C. Machado, S. Leal, and P. Araújo Gonçalves et al. Stent thrombosis with second- versus first-generation drug-eluting stents in real-world percutaneous coronary intervention: analysis of 3806 consecutive procedures from a large-volume single-center prospective registry J Invasive Cardiol 25 7 2013 330 336
18. Y.J. Youn, J.W. Lee, S.G. Ahn, S.H. Lee, H.H. Choi, and H. Choi et al. Study design and rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing Three 2nd-Generation Drug-Eluting Stents in Real-World Practice" (CHOICE trial) Am Heart J 166 2 2013 224 229
19. N. Kipshidze et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions J Am Coll Cardiol 44 2004 733 739
20. T. Xi et al. In vitro and in vivo changes to PLGA/sirolimus coating on drug eluting stents Biomaterials 31 2010 5151 5158
21. C.M. Bünger et al. Iliac anastomotic stenting with a sirolimus-eluting biodegradable poly-l-lactide stent: a preliminary study after 6 weeks J Endovasc Ther 13 2006 630 639
22. K. Sternberg et al. In vitro study of drug-eluting stent coatings based on poly(l-lactide) incorporating cyclosporine A - drug release, polymer degradation and mechanical integrity J Mater Sci - Mater Med 18 2007 1423 1432
23. J. Ge et al. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries Catheter Cardiovasc Interv 69 2007 198 202
24. D. Dudek, Y. Onuma, J.A. Ormiston, L. Thuesen, K. Miquel-Hebert, and P.W. Serruys Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial EuroIntervention 7 2012 1060 1061
25. S.J. Kim et al. Development of a biodegradable sirolimus-eluting stent coated by ultrasonic atomizing spray J Nanosci Nanotechnol 11 2011 5689 5697
26. J.A. Ormiston, M.W. Webster, and G. Armstrong First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-l-lactic acid everolimus-eluting coronary stent Catheter Cardiovasc Interv 69 2007 128 131
27. P.W. Serruys et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes J Am Coll Cardiol 58 2011 1578 1588
28. S.P. Valappil, S.K. Misra, A.R. Boccaccini, and I. Roy Biomedical applications of polyhydroxyalkanoates: an overview of animal testing and in vivo responses Expert Rev Med Devices 3 2006 853 868
29. N. Grabow, D.P. Martin, K.P. Schmitz, and K. Sternberg Absorbable polymer stent technologies for vascular regeneration J Chem Technol Biotechnol 85 2010 1
30. F. Jantzen et al. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells J Physiol Pharmacol 58 2007 503 514
31. J.W. Jukema, T.A. Ahmed, J.J. Verschuren, and P.H. Quax Restenosis after PCI. Part 2: prevention and therapy Nat Rev Cardiol 9 2012 79 90
32. S. Garg, and P.W. Serruys Coronary stents: looking forward J Am Coll Cardiol 56 2010 S43 S78
33. R.A. Byrne, M. Joner, and A. Kastrati Polymer coatings and delayed arterial healing following drug-eluting stent implantation Minerva Cardioangiol 57 2009 567 584
34. L. Pendyala, R. Jabara, K. Robinson, and N. Chronos Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing J Interv Cardiol 22 2009 37 48
35. F. Vogt et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent Eur Heart J 25 2004 1330 1340
36. M.G. Whitbeck, and R.J. Applegate Second generation drug-eluting stents: a review of the everolimus-eluting platform Clin Med Insights Cardiol 7 2013 115 126
37. Y. Onuma, K. Miquel-Hebert, P.W. Serruys SPIRIT II Investigators Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial EuroIntervention 8 9 2013 1047 1051
38. Y.S. Chatzizisis, A.U. Coskun, M. Jonas, E.R. Edelman, C.L. Feldman, and P.H. Stone Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior J Am Coll Cardiol 49 2007 2379 2393
39. A. Curcio, D. Torella, and C. Indolfi Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy Circ J 75 2011 1287 1296
40. A.V. Finn et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialisation Circulation 115 2007 2435 2441
41. S. Reitsma, D.W. Slaaf, H. Vink, M.A. van Zandvoort, and M.G. Oude Egbrink The endothelial glycocalyx: composition, functions, and visualization Pflugers Arch 454 2007 345 359
42. M. Gouverneur, B. Berg, M. Nieuwdorp, E. Stroes, and H. Vink Vasculoprotective properties of the endothelial glycocalyx: effects of fluid shear stress J Intern Med 259 2006 393 400
43. Barker et al. Observation and characterisation of the glycocalyx of viable human endothelial cells using confocal laser scanning microscopy Phys Chem Chem Phys 6 2004 1006 1011
44. M. Nieuwdorp, M.C. Meuwese, H. Vink, J.B. Hoekstra, J.J. Kastelein, and E.S. Stroes The endothelial glycocalyx: a potential barrier between health and vascular disease Curr Opin Lipidol 16 2005 507 511
45. S. Kawashima, and M. Yokoyama Dysfunction of endothelial nitric oxide synthase and atherosclerosis Arterioscler Thromb Vasc Biol 24 2004 998 1005
46. S. Kawashima et al. Endothelial NO synthase overexpression inhibits lesion formation in mouse model of vascular remodeling Arterioscler Thromb Vasc Biol 21 2001 201 207
47. K. Fujiwara Platelet endothelial cell adhesion molecule-1 and mechanotransduction in vascular endothelial cells J Intern Med 259 2006 373 380
48. D. Gratzinger, M. Barreuther, and J.A. Madri Platelet-endothelial cell adhesion molecule-1 modulates endothelial migration through its immunoreceptor tyrosine-based inhibitory motif Biochem Biophys Res Commun 301 2003 243 249
49. A. RayChaudhury, M. Elkins, D. Kozien, and M.T. Nakada Regulation of PECAM-1 in endothelial cells during cell growth and migration Exp Biol Med (Maywood) 226 2001 686 691
50. I. Fleming, B. Fisslthaler, M. Dixit, and R. Busse Role of PECAM-1 in the shear-stress-induced activation of Akt and the endothelial nitric oxide synthase (eNOS) in endothelial cells J Cell Sci 118 2005 4103 4111
51. H.K. Eltzschig, and P. Carmeliet Hypoxia and inflammation N Engl J Med 364 7 2011 656 665 10.1056/NEJMra0910283 Feb 17
52. H.K. Eltzschig, C.F. Macmanus, and S.P. Colgan Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface Trends Cardiovasc Med 18 3 2008 103 107 10.1016/j.tcm.2008.01.006 Apr
53. M. Faigle, J. Seessle, S. Zug, K.C. El Kasmi, and H.K. Eltzschig ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia PLoS ONE 3 7 2008 e2801 10.1371/journal.pone.0002801 Jul 30
54. A.S. Yong et al. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel Blood 117 2011 11 20
55. W. Yin, S.K. Shanmugavelayudam, and D.A. Rubenstein The effect of physiologically relevant dynamic shear stress on platelet and endothelial cell activation Thromb Res 127 2011 235 241
56. P.H. Blit, W.G. McClung, J.L. Brash, K.A. Woodhouse, and J.P. Santerre Platelet inhibition and endothelial cell adhesion on elastin-like polypeptide surface modified materials Biomaterials 32 2011 5790 5800
57. G.V. Born Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 194 1962 927 929
58. F. Franconi et al. Effect of gamma-hydroxybutyric acid on human platelet aggregation in vitro Thromb Res 102 2001 255 260
59. A.M. Lincoff, J.G. Furst, S.G. Ellis, R.J. Tuch, and E.J. Topol Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model J Am Coll Cardiol 29 4 1997 808 816
60. N. Grabow et al. A biodegradable slotted tube stent based on poly(l-lactide) and poly(4-hydroxybutyrate) for rapid balloon-expansion Ann Biomed Eng 35 2007 2031 2038
61. G.W. Stone et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008
62. M. Joner et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
63. S.H. Hofma et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation Eur Heart J 27 2006 166 170